📣 VC round data is live. Check it out!

Beiersdorf Valuation Multiples

Discover revenue and EBITDA valuation multiples for Beiersdorf and similar public comparables like Essity, Kao, Yunnan Baiyao Group, Church & Dwight and more.

Beiersdorf Overview

About Beiersdorf

Beiersdorf is a Germany-based company that produces personal-care products, with a focus on manufacturing cosmetic products. The company operates through two business segments. The consumer segment provides skincare and beauty care products and operates portfolio brands such as Nivea, Eucerin, La Prairie, Labello, Hansaplast, Elastoplast, and Florena. The other business segment markets self-adhesive system and product solutions, primarily for industrial customers, under the Tesa brand. Beiersdorf is majority-owned by Maxingvest.


Founded

1882

HQ

Germany

Employees

22.8K

Financials (LTM)

Revenue: $11B
EBITDA: $2B

EV

$15B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Beiersdorf Financials

Beiersdorf reported last 12-month revenue of $11B and EBITDA of $2B.

In the same LTM period, Beiersdorf generated $7B in gross profit, $2B in EBITDA, and $1B in net income.

Revenue (LTM)


Beiersdorf P&L

In the most recent fiscal year, Beiersdorf reported revenue of $12B and EBITDA of $2B.

Beiersdorf is profitable as of last fiscal year, with gross margin of 58%, EBITDA margin of 17%, and net margin of 10%.

See analyst estimates for Beiersdorf
LTMLast FY202320242025202620272028
Revenue$11B$12B$11B$12B$12B
Gross Profit$7B$7B$6B$7B$7B
Gross Margin58%58%57%58%58%
EBITDA$2B$2B$2B$2B$2B
EBITDA Margin17%17%17%18%17%
EBIT Margin14%14%12%14%14%
Net Profit$1B$1B$863M$1B$1B
Net Margin10%10%8%9%10%

Financial data powered by Morningstar, Inc.

Beiersdorf Stock Performance

Beiersdorf has current market cap of $18B, and enterprise value of $15B.

Market Cap Evolution


Beiersdorf's stock price is $82.77.

Beiersdorf share price increased by 0.4% in the last 30 days, and decreased by 40.5% in the last year.

Beiersdorf has an EPS (earnings per share) of $5.06.

See more trading valuation data for Beiersdorf
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$15B$18B0.0%0.4%-34.9%-40.5%$5.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Beiersdorf Valuation Multiples

Beiersdorf trades at 1.3x EV/Revenue multiple, and 7.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Beiersdorf

EV / Revenue (LTM)


Beiersdorf Financial Valuation Multiples

As of May 4, 2026, Beiersdorf has market cap of $18B and EV of $15B.

Beiersdorf has a P/E ratio of 16.4x.

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.3x1.4x1.3x1.3x
EV/EBITDA7.8x7.6x8.2x7.5x7.6x
EV/EBIT9.7x9.5x11.1x9.7x9.5x
EV/Gross Profit2.3x2.3x2.4x2.2x2.3x
P/E16.4x16.4x21.0x16.9x16.4x
EV/FCF23.9x33.3x30.5x16.3x40.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Beiersdorf Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Beiersdorf Margins & Growth Rates

Beiersdorf decreased revenue by 0% and EBITDA by 3% in the last fiscal year.

In the most recent fiscal year, Beiersdorf reported gross margin of 58%, EBITDA margin of 17%, and net margin of 10%.

See estimated margins and future growth rates for Beiersdorf

Beiersdorf Margins

Last FY202420252026202720282029
Gross Margin58%58%58%58%
EBITDA Margin17%18%17%17%
EBIT Margin14%14%14%13%
Net Margin10%9%10%9%
FCF Margin4%8%3%8%

Beiersdorf Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(0%)4%0%(0%)
Gross Profit Growth(0%)6%(1%)(0%)
EBITDA Growth(3%)9%(1%)(3%)
EBIT Growth(4%)15%2%(4%)
Net Profit Growth(1%)24%3%(1%)
FCF Growth114%87%(59%)159%

Data powered by FactSet, Inc. and Morningstar, Inc.

Beiersdorf Operational KPIs

Beiersdorf's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

Beiersdorf's Rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Beiersdorf's Rule of X is 16% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Beiersdorf
LTMLast FY202320242025202620272028
Rule of 4019%17%———
Bessemer Rule of X22%16%———
Revenue per Employee—$0.5M———
Opex per Employee—$0.2M———
S&M Expenses to Revenue35%35%34%35%35%
G&A Expenses to Revenue6%6%6%6%6%
R&D Expenses to Revenue4%4%3%4%4%
Opex to Revenue—44%45%45%44%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Beiersdorf Competitors

Beiersdorf competitors include Essity, Kao, Yunnan Baiyao Group, Church & Dwight, Ulta Beauty, Cooper Companies, Puig Brands, Godrej Consumer Products, APR Co. and Marico.

Most Beiersdorf public comparables operate across Health & Beauty.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Essity1.4x1.4x7.5x7.6x
Kao1.5x1.5x10.2x9.9x
Yunnan Baiyao Group2.0x2.0x12.6x13.6x
Church & Dwight3.9x4.0x18.8x17.1x
Ulta Beauty2.0x2.0x13.4x13.3x
Cooper Companies3.6x3.5x11.3x10.9x
Puig Brands2.0x2.0x9.2x9.7x
Godrej Consumer Products6.9x7.1x32.7x34.4x

This data is available for Pro users. Sign up to see all Beiersdorf competitors and their valuation data.

Start Free Trial

Beiersdorf M&A Activity

Beiersdorf has acquired 3 companies to date.

Last acquisition by Beiersdorf was on December 16th 2022. Beiersdorf acquired S-Biomedic for $645M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Beiersdorf

S-Biomedic
Chantecaille
Coppertone
Description
S-Biomedic is a UK-based biotech firm engineering microbiome-targeted therapies for skin disorders like acne, eczema, and rosacea. Headquartered in London, the company formulates products using selected beneficial bacteria strains to restore microbial balance, applicable in prescription dermatology and over-the-counter cosmetics through partnerships with contract manufacturers.
Chantecaille is a New York-based luxury beauty brand offering botanical skincare, makeup, and fragrances. The company produces products like Bio Lifting Serum+, Future Skin cushion foundation, and Wild Orchid eye cream using plant extracts without parabens or synthetic dyes. Chantecaille sells through Neiman Marcus, Nordstrom, and its website, supporting wildlife conservation via product sales.
Coppertone is a leading US sunscreen brand owned by Beiersdorf since 2021, offering lotions, sprays, and sticks with SPF levels from 15 to 100+. Its Sport and Water Babies lines protect against UVA/UVB rays during outdoor activities. Coppertone manufactures at facilities in Tennessee and distributes through Walmart, Target, and pharmacies nationwide. Introduced in 1944, the brand holds over 20% US market share in sun care.
HQ CountryUnited StatesUnited StatesUnited States
HQ City
Milwaukee, WI
New York City, NY
Stamford, CT
Deal Date16 Dec 202222 Dec 202113 May 2019
Valuation$645M$690M$550M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Beiersdorf acquisitions and their M&A valuation multiples.

Start Free Trial

Beiersdorf Investment Activity

Beiersdorf has invested in 8 companies to date.

Latest investment by Beiersdorf was on December 8th 2025. Beiersdorf invested in Melt&Marble in their $9M Series A round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Beiersdorf

Melt&Marble
Cellvie
DePoly
Vincere Biosciences
Description
Melt&Marble is a precision fermentation company producing animal-free fats for plant-based foods. It engineers microbes to create structured lipids mimicking beef tallow and pork lard, used in burgers and pastries by food manufacturers. Amsterdam-headquartered since 2020, the startup partners with ingredient suppliers to supply fats for hybrid meat products across Europe.
Cellvie is a Basel-based biopharma company engineering mitochondria transplantation therapies to treat ischemia-reperfusion injuries in heart attacks and strokes. Licensing technology from Harvard researchers, their lead candidate CV-1 delivers functional mitochondria via extracellular vesicles to restore cellular energy production. Cellvie conducts preclinical studies in porcine models and collaborates with European clinics for acute cardiovascular applications.
DePoly is a Netherlands-based chemical recycling firm that depolymerizes post-consumer PET plastics and polyester textiles into monomers at ambient temperature. Its patented process eliminates pre-washing, sorting, or separation needs, yielding high-purity terephthalic acid and ethylene glycol for reuse in virgin-quality production. Operating pilot facilities in Amsterdam, DePoly partners with textile brands and plastic converters to scale circular economy solutions, targeting waste from bottles and apparel across Europe.
Vincere Biosciences is a Johnson & Johnson JLABS incubator company developing therapeutics targeting the progression of Parkinson's disease. The San Diego-based biotech focuses on novel drug candidates to address neurodegeneration.
HQ CountrySwedenUnited StatesSwitzerlandUnited States
HQ City
Göteborg
Houston, TX
Sion
—
Deal Date8 Dec 20259 Sep 202529 Apr 20251 Apr 2025
RoundSeries ASeedSeedSeries A
Raised$9M$5M$23M$5M
InvestorsBeiersdorf; Catalyze Capital; Chalmers Ventures AB; European Innovation Council Fund; Industrifonden; ValioBeiersdorf; KIZOO Technology Capital; Taiho VenturesAngel Invest; BASF Venture Capital; Beiersdorf; Founderful; MassMutual Ventures; Syensqo Ventures; Zürcher Kantonal BankAlumni Ventures; Beiersdorf; Beresford Ventures; Daewoong Pharmaceutical; Draper Associates; FreeMind Investments; HanAll Biopharma; Healthspan Capital; Kastor Capital; KreaMedica; LongGame; Michael J. Fox Foundation
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Beiersdorf investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Beiersdorf

When was Beiersdorf founded?Beiersdorf was founded in 1882.
Where is Beiersdorf headquartered?Beiersdorf is headquartered in Germany.
How many employees does Beiersdorf have?As of today, Beiersdorf has over 22K employees.
Is Beiersdorf publicly listed?Yes, Beiersdorf is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Beiersdorf?Beiersdorf trades under BEI ticker.
When did Beiersdorf go public?Beiersdorf went public in 1929.
Who are competitors of Beiersdorf?Beiersdorf main competitors include Essity, Kao, Yunnan Baiyao Group, Church & Dwight, Ulta Beauty, Cooper Companies, Puig Brands, Godrej Consumer Products, APR Co., Marico.
What is the current market cap of Beiersdorf?Beiersdorf's current market cap is $18B.
What is the current revenue of Beiersdorf?Beiersdorf's last 12 months revenue is $11B.
What is the current revenue growth of Beiersdorf?Beiersdorf revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of Beiersdorf?Current revenue multiple of Beiersdorf is 1.3x.
Is Beiersdorf profitable?Yes, Beiersdorf is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Beiersdorf?Beiersdorf's last 12 months EBITDA is $2B.
What is Beiersdorf's EBITDA margin?Beiersdorf's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Beiersdorf?Current EBITDA multiple of Beiersdorf is 7.8x.
What is the current FCF of Beiersdorf?Beiersdorf's last 12 months FCF is $634M.
What is Beiersdorf's FCF margin?Beiersdorf's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of Beiersdorf?Current FCF multiple of Beiersdorf is 23.9x.
How many companies Beiersdorf has acquired to date?As of May 2026, Beiersdorf has acquired 3 companies.
What was the largest acquisition by Beiersdorf?$690M acquisition of Chantecaille on 22nd December 2021 was the largest M&A Beiersdorf has done to date.
What companies Beiersdorf acquired?Beiersdorf acquired Chantecaille, S-Biomedic, and Coppertone.
In how many companies Beiersdorf has invested to date?As of May 2026, Beiersdorf has invested in 8 companies.
What was the last Beiersdorf investment?On 8th December 2025 Beiersdorf invested in Melt&Marble, participating in a $9M Series A round, alongside Catalyze Capital, Chalmers Ventures AB, European Innovation Council Fund, Industrifonden, and Valio.
In what companies Beiersdorf invested in?Beiersdorf invested in DePoly, DeepLife, Melt&Marble, Vincere Biosciences, Cellvie, S-Biomedic, Salvalco, and Dermanostic.

See public comps similar to Beiersdorf

Lists including Beiersdorf

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial